10月24日，西点药业大宗交易成交52.12万股，成交额1304.99万元，占当日总成交额的27.09%，成交价 25.04元，较市场收盘价31.31元折价20.03%。 | 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | | | | (元) | (万股/万份) | (万元) | | | | 2025-10-24 | 301130 | 西岸药补 | 25.04 | 52.12 | 1,304.9国泰海通证券股份 | | 国泰海通证券股份 | | | | | | | | 有限公司北京朝阳 | 有限公司吉林南京 | | | | | | | 门证监管业部 | 街市安营业部 | | ...

Core Viewpoint - The company has existing flu medication products and is developing new antiviral treatments, indicating a strong position in the respiratory infection market [2]. Product Overview - The company currently markets a mature flu medication, Compound Acetaminophen and Amantadine Capsules [2]. - An antiviral tablet is expected to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [2]. Research and Development - The company is conducting research on "Rui Xiang Su" for its effects on viral pneumonia in mouse models, showing safety and efficacy [2]. - A patent has been obtained for the application of "Rui Xiang Su" in the preparation of drugs for treating viral pneumonia [2]. - The company is the sole producer and seller of "Rui Xiang Su" capsules in China [2].

Core Viewpoint - The company has recently obtained an invention patent certificate for the synthesis method of a core product, which signifies a strategic enhancement of its technological capabilities and intellectual property protection [1][2]. Group 1: Patent Acquisition - The company has received an invention patent certificate from the National Intellectual Property Administration of China for a synthesis method of Rhizoma Anemones [1]. - The synthesis method involves using gallic acid and malic acid as raw materials, with concentrated sulfuric acid as a condensation catalyst, achieving a product yield of over 90% and purity of up to 99% [1]. Group 2: Strategic Implications - The acquisition of this patent reflects not only a technological advancement but also a strategic move to strengthen core technologies and lay a foundation for future development [2]. - The company now holds two patents related to the synthesis process of Rhizoma Anemones, which will enhance its core competitiveness in technological innovation and support the development of this key product [2].

证券日报网讯 10月20日晚间，西点药业发布公告称，公司于近日取得国家知识产权局颁发的发明专利 证书，专利名称为"一种瑞香素的合成方法"。 （文章来源：证券日报） ...

Core Points - The company has recently obtained an invention patent certificate from the National Intellectual Property Administration of the People's Republic of China [1] - The patent is titled "A Synthesis Method of Ruscogenin" and has a patent number of 8338136 [1] - The patent application date was July 28, 2025, and the authorization announcement date was October 10, 2025 [1] - The patent is owned by Jilin Xidian Pharmaceutical Technology Development Co., Ltd., and has a validity period of 20 years [1]

吉林省西点药业科技发展股份有限公司（以下简称"公司"）于近日取得中 华人民共和国国家知识产权局颁发的发明专利证书。具体情况如下： | 专利证书 | 专利 | 专利申请 | 授权公 | 专利 | 专利名称 | 专利号 | 专利权人 | 备注 | 号 | 类型 | 日 | 告日 | 期限 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 吉林省西点 | 2025 | 年 | 2025 | 年 | 一种瑞香素 | ZL | 2025 | 1 | 第 | 8338136 | 发明 | 药业科技发 | | | | | | | 1 | 07 | 月 | 28 | 10 | 月 | 10 | 20 | 年 | 注 | 1 | 的合成方法 | 1037835.9 | 号 | 专利 | 展股份有限 | 日 | 日 | | 公司 | | | | | | | | | | | | | | | | | | 注 1：本发明涉及化学药物合成技术领域 ...

格隆汇10月15日｜西点药业公告，持股5%以上的股东横琴鼎典股权投资基金合伙企业（有限合伙）所 持有的公司部分股份被司法冻结。本次冻结股份数量为256.7万股，占其所持股份比例为42.69%，占公 司总股本比例为3.36%。横琴鼎典累计被冻结股份数量为256.7万股，占其所持股份比例为42.69%，占公 司总股本比例为3.36%。此次冻结原因是涉诉，冻结期限为2025年10月13日至2028年10月12日。横琴鼎 典不属于公司控股股东或实际控制人，此次股份冻结不会导致公司控制权变更，也不会对公司的持续经 营产生不利影响。 ...

关于持股 5%以上的股东股份被司法冻结的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"或"本公司"） 于近日通过中国证券登记结算有限责任公司深圳分公司系统查询，获悉公司持股 5%以上的股东横琴鼎典股权投资基金合伙企业（有限合伙）（以下简称"横琴鼎 典"）所持有本公司的部分股份被司法冻结，具体事项如下： 2、股东股份累计被冻结情况 截至本公告披露日，横琴鼎典所持股份累计被冻结情况如下： 证券代码：301130 证券简称：西点药业 公告编号：2025-065 吉林省西点药业科技发展股份有限公司 | 股东名称 | 持股数量 | 持股比例 | 累计被冻结数量 | 合计占其所 | 合计占公司 | | --- | --- | --- | --- | --- | --- | | | （万股） | | （万股） | 持股份比例 | 总股本比例 | | 横琴鼎典 | 601.3154 | 7.86% | 256.6989 | 42.69% | 3.36% | | 合计 | 601.3154 | 7.86% | 256. ...

证券代码：301130 证券简称：西点药业 公告编号：2025-064 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金进行现金管理到期赎回及闲置自有资金 进行委托理财部分赎回并继续进行现金管理和委托理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司 ...

Group 1 - The core viewpoint of the news is that Xidian Pharmaceutical experienced a decline in stock price and trading volume on September 25, with significant financing activities indicating a high level of market interest despite the drop [1] - On September 25, Xidian Pharmaceutical's stock fell by 0.84%, with a trading volume of 23.24 million yuan. The financing buy-in amount was 1.72 million yuan, while the financing repayment was 2.78 million yuan, resulting in a net financing buy-in of -1.06 million yuan [1] - As of September 25, the total balance of margin trading for Xidian Pharmaceutical was 111 million yuan, which accounted for 4.91% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Xidian Pharmaceutical increased to 8,099, representing a 13.04% rise, while the average circulating shares per person decreased by 11.85% to 7,212 shares [2] - For the first half of 2025, Xidian Pharmaceutical reported operating revenue of 128 million yuan, a slight decrease of 0.51% year-on-year, while the net profit attributable to the parent company was 24.94 million yuan, reflecting a growth of 2.02% year-on-year [2] - Since its A-share listing, Xidian Pharmaceutical has distributed a total of 63.34 million yuan in dividends, with 52.83 million yuan distributed over the past three years [2]